Clearly tavr is the selling point now. The valuations page is interesting and shows this clearly, with tavr many multiples of adapt. $5.6m for infusion as the base valuation means it's unlikely the proposed sale will be much of an answer to financial issues, but getting rid of it will help with getting more r&d grants / rebates.
New analyst report from NDF Research, page-4
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.90 |
Change
0.200(1.57%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $12.62 | $12.99 | $12.61 | $210.9K | 16.57K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1099 | $12.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.98 | 246 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |